@article{6c9529632d744e89b6c4590140e2ff0b,
title = "Current Progress and Advances in Gastrointestinal Cancers: Highlights from the 2022 Annual American Society of Clinical Oncology (ASCO) Gastrointestinal Meeting",
abstract = "Purpose: To provide an overview of the key findings from studies in upper gastrointestinal, hepatobiliary, pancreas, and colorectal malignancies presented at ASCO GI 2022. Methods: We reviewed the abstracts presented at ASCO GI 2022. The studies highlighted were selected by the authors based on their significant discoveries and potential impact on clinical practice. Results and Conclusion: This year{\textquoteright}s hybrid ASCO-GI symposium (2022) introduced many promising new treatment strategies in GI oncology, with several changes in clinical practice for patients with advanced hepatocellular carcinoma (HCC), cholangiocarcinoma, and metastatic colorectal cancer (CRC).",
keywords = "ASCO-GI symposium, Colorectal cancer, Esophygeal cancer, Gastric cancer, Hepatobiliary cancers, Pancreatic cancer",
author = "Sepideh Gholami and Mustafa Abidalhassan and May Cho and Anwaar Saeed and Rocha, {Flavio G.}",
note = "Funding Information: AS reports research grants (to institution) from AstraZeneca, Bristol Myers Squibb, Merck, Clovis, Exelixis, Actuate Therapeutics, Incyte Corporation, Daiichi Sankyo, Five Prime Therapeutics, Amgen, Innovent Biologics, Dragonfly Therapeutics, KAHR Medical, Biontech, and advisory board fees from AstraZeneca, Bristol Myers Squibb, Exelixis, Pfizer, and Daiichi Sankyo. FGR reports Consultant-Medtronic, Oncosil; Advisory Board, Astra Zeneca; Research Funding, Gunze. MC reports Speaker{\textquoteright}s Bureau for Pfizer, Natera, Taiho, BMS, AstraZeneca, DSI; Advisory Board and Honoraria for Amgen, Incyte, Eisai, Ipsen, Astellas, Taiho, Exelixis, QED, I-Mab, Tempus, Seattle Genetics, HelioDx, Bayer, AstraZeneca, Genentech/Roche, Pfizer, Natera, Taiho, BMS, Basilea. SG report Consulting or Advisory Board for Signatera, QED Therapeutics, TRUSELTIQ; Speakers{\textquoteright} Bureau for Helsinn Therapeutics. MA has no relevant financial or non-financial interests to disclose. Publisher Copyright: {\textcopyright} 2022, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",
year = "2022",
doi = "10.1007/s12029-022-00849-5",
language = "English (US)",
journal = "Journal of Gastrointestinal Cancer",
issn = "1941-6628",
publisher = "Humana Press",
}